Council Member Biography
William Shannon, PhD, is an Associate Professor of Biostatistics at Washington University School of Medicine, since 1995; and Founder and President of BioRankings, a pharma IT firm, since January 2007. Dr. Shannon has over 20 years of applied biostatistical expertise in biomedical, pharmaceutical, and biotech research. He has 100 peer-reviewed publications in areas such as oncology, genetics, cardiology, pulmonology infectious disease, sleep medicine, health care delivery, statistics, and other areas. By making complex biostatistical ideas understandable, Dr. Shannon can help companies gain insight on the strengths and weaknesses of pre-clinical data and clinical trials that may impact a company's long term viability, and understanding of statistical data to protect investment. (This is me - Update Profile)
Employment History
- 2007 - Unspecified
- Founder and President, BioRankings, LLC
- 1995 - Unspecified
- Associate Professor (Tenured), THE WASHINGTON UNIVERSITY
GLG NewsSM Analyses by William Shannon
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
The data and news behind the FDA decison
January 31, 2010
FDA to Re-evaluate Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease | www.parenteaubc.com
The FDA announced plans for an advisory review board in 2010 to re-evaluate erythropoiesis-stimulating agents (ESAs) usage and dosing for the treatment of anemia in chronic kidney disease. This decision followed publication of a report indicating ESAs provide no benefit in outcome compared to placebo, and increases stroke rates.
-
Cancer Immunotherapy Explained
January 31, 2010
Immunotherapy Demystified: Investing In High Risk, High Reward Opportunities In Cancer Therapeutics | www.parenteaubc.com
The Parenteau BioConsultants and BioRankings Alliance, both GLG consultants, have released a free ebook for investors and biotech executives -- "Immunotherapy Demystified: Investing In High Risk, High Reward Opportunities In Cancer Therapeutics".This ebook presents the necessary background of the biology and statistics of this field to help the investor avoid the hype and spin behind cancer immunotherapies, and reduce the risk of their investment decisions.
-
Meta-analysis of probiotics in atopic dermatitis
April 16, 2009
Probiotics for the treatment or prevention of atopic dermatitis: a review of the evidence from randomized controlled trials. | www.ncbi.nlm.nih.gov
The use of meta-analysis to evaluate probiotics in this condition is commendable. The abstract suggests that improvement may be real, but the evidence presented indicates that probiotics may be ineffective on careful reading. The abstract is lacking information needed to determine the quality of the meta-analysis and whether its results/suggestions should be considered in investment decisions.
-
New FDA effort takes aim at genomics: Inherent risk to investors
February 6, 2009
New FDA Effort to Take Aim at Genomics | www.genomeweb.com
The risk to an investor in genomic or personalized medicine is significant and a clear understanding of the low power and high risk of false-positives needs to be kept in mind. The establishment at the FDA of a senior scientist to oversee and coordinate genomic activities is necessary but not necessarily sufficient to insure that future genomic treatments are effective.
-
Eli Lilly's Personal Medicine Goal
November 27, 2008
Personal medicine is goal of Eli Lilly & Co. | www.azcentral.com
The Chairman of Eli Lilly announcing that personalized medicine (e.g., pharmacogenetics) is a major shift in strategy for big pharma could impact in a significant way the market share for new drugs and the amount of money for research needed to bring a targeted therapy to market. If this strategy is widely accepted the likely impact on small biotech firms will be a significant increase in their value and more acquisitions.
GLG Study Groups with William Shannon(?)
| Study Group Name | No. Members |
|---|---|
| Biostatisticians | 358 |
| Biostatisticians (US) | 254 |
GLG Live Meetings with William Shannon(?)
William Shannon has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.